Final results of a phase I randomized, parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/taxol (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer. - Pouillart,P.; Fumoleau,P.; Romieu,G. (Proc Ann Meet Soc Clin Oncol, 1999)